¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Framingham Heart study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® heart ÇÑ±Û ½ÉÀå
¼³¸í   
  ½ÉÀåÀº °¡½¿ÀÇ Áß¾Ó¿¡ À§Ä¡Çϸ砿À¸¥Âʰú ¿ÞÂʹÝÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. °¢°¢Àº Á¤¸Æ¿¡¼­ Çǰ¡ µé¾î¿À´Â ¹æ°ú µ¿¸ÆÀ¸·Î ÇǸ¦ ³»º¸³»´Â ½ÇÀÌ ÀÖ´Ù. ½ÉÀåÀº Á¤Áß¾Ó¼±¿¡¼­ ¿ÞÂÊ¿¡ ³õ¿© ÀÖ´Ù.
  
  ½ÉÀåÀÇ 2°³ÀÇ ½É¹æ°ú 2°³ÀÇ ½É½Ç, ±×¸®°í ½É¹æ»çÀÌÀÇ ½É¹æÁß°Ý, ½É½Ç»çÀÌÀÇ ½É½ÇÁß°ÝÀÌ Á¸ÀçÇÑ´Ù. ½É½ÇÀº Ç÷¾×À» ÁַΠ¼øÈ¯½Ã۴ ÈûÀ» ³»´Â °÷À¸·Î °­ÇÑ ±ÙÀ°ÃþÀÌ Á¸À縦 ÇÑ´Ù. ¹Ý¸é¿¡ ½É¹æÀº ½É½Ç¿¡ µé¾î°¡±âÀü¿¡ ÀϽÃÀûÀ¸·Î Çǰ¡ ¸ðÀ̴ °÷À¸·Î ±ÙÀ°ÃþÀÇ ¹ß´ÞÀÌ ¹Ì¾àÇÏ´Ù. ½É¹æ°ú ½É½Ç»çÀÌ¿¡ »ï÷ÆÇ°ú ½Â¸ðÆÇ, ½É½ÇÀÇ À¯Ãâ·Î¿¡ ´ëµ¿¸ÆÆÇ°ú Æóµ¿¸ÆÆÇÀÌ ÀÖ´Ù. À̰͵éÀº Ç÷¾×ÀÌ È帣´Â ¹æÇâ¿¡ °Å½½·¯ ÁøÇàÇϴ °ÍÀ» ¸·´Â ±â´ÉÀ» ÇÑ´Ù. ±×¸®°í ½ÉÀå¿¡´Â ½ÉÀåÀÇ ±ÙÀ°¿¡ Ç÷¾×À» °ø±ÞÇϴ °ü»óµ¿¸ÆÀÌ ÀÖ´Ù. ÀÌ ½ÉÀ嵿¸ÆÀº ½ÉÀåÀ» ½×µíÀÌ Á¸ÀçÇÑ´Ù.
  
  ½ÉÀå¹Úµ¿ÀÇ ½ÅÈ£´Â Æ¯¼öÇÑ ÀåÄ¡¿¡ ÀÇÇØ¼­ ¹ß»ýÀÌ µÇ°í Æ¯¼öÇÑ Àüµµ°è¸¦ ÅëÇØ¼­ ÀüüÀÇ ½ÉÀåÀ¸·Î ÀüµµµÈ´Ù. ½ÉÀå¹Úµ¿ÀÇ ½ÅÈ£´Â ¿ì¼± ¿ì½É¹æ¿¡ À§Ä¡Çϴ µ¿¹æ°áÀý(SA node)¶ó´Â °÷¿¡¼­ ¿ì¼± »ý±ä´Ù. ¿©±â¿¡¼­ º¸³»´Â Àü±âÀû ½ÅÈ£°¡ ¹Ù·Î ½ÉÀåÀ» ¶Ù°ÔÇϴ ½ÅÈ£ÀΠ°ÍÀÌ´Ù. ÀÌ ½ÅÈ£·Î ¸»¹Ì¾Ï¾Æ ½É¹æÀÌ ¿ì¼± ¼öÃàÀ» ÇÑ´Ù. ±×¸®°í´Â ½É¹æ°ú ½É½Ç»çÀÌ¿¡ À§Ä¡Çϴ ¹æ½Ç°áÀý(AV node)¶ó´Â °÷¿¡ ÀÏÁ¤ÇϰԠÁ¤ÇØÁø Åë·Î¾øÀÌ ÀüüÀÇ ½É¹æÀ» ÅëÇØ¼­ Àü´ÞÀÌ µÇ°í ÀÌ ½ÅÈ£¸¦ ¹ÞÀº ¹æ½Ç°áÀý(AV node)´Â È÷½º ´Ù¹ß(His bundle)°ú ½ÉÀåÀüµµ±ÙÀ°¼¶À¯¸¦ ÅëÇØ¼­ ½É½ÇÀÇ ½ÉÀå±ÙÀ°¿¡°Ô ÀÌ ½ÅÈ£¸¦ º¸³»Á־ɽDZÙÀ°À» ¼öÃàÇϰԠÇÑ´Ù. È÷½º´Ù¹ß°ú ½ÉÀåÀüµµ±ÙÀ°¼¶À¯´Â ÀüüÀÇ ½É½ÇÀÇ ½É±Ù¼¶À¯¿¡ µ¿½Ã¿¡ Àü±âÀû ½ÅÈ£¸¦ º¸³»¾î ÁÙ ¼ö ÀÖ°Ô Çϴ ÀÏÁ¾ÀÇ Àü±âÁÙ°ú °°Àº ¿ªÇÒÀ» ÇÑ´Ù.
  
  ½ÉÀå
¿µ¹® heart failure ÇÑ±Û ½ÉÀå±â´É»ó½Ç
¼³¸í   
  ¸öÀÇ Á¶Á÷À̳ª ±â°ü¿¡¼­ ´ë»ç¿¡ ÇÊ¿äÇÑ ¸¸Å­ ÃæºÐÇÑ ¾çÀÇ Ç÷¾×À» °ø±ÞÇÒ ¼ö ¾øÀ» Á¤µµ·Î ½ÉÀå±â´ÉÀÌ ÀúÇϵǾî Àִ »óÅÂÀÌ´Ù. ½ÉÀå±â´É»ó½ÇÀº ½É±ÙÀÌ ¼öÃàÇÒ ´É·ÂÀÌ ÀúÇϵǾúÀ» ¶§³ª ½ÉÀå¿¡ ½É¹ÚÃâÀ» Çϱâ À§ÇÑ ¾Ð·ÂÀÌ Á¤»óº¸´Ù Áõ°¡µÇ¾î Á¤»óÀÇ ½ÉÀåÀÇ ¼öÃàÀ¸·Î´Â ÃæºÐÇÑ ¾çÀÇ Ç÷¾×À» °ø±ÞÇÒ ¼ö ¾ø´Â °æ¿ì, ±×¸®°í ½ÉÀå±ÙÀ°, ½ÉÀå¿¡ °É¸®´Â ¾Ð·ÂÀº Á¤»óÀ̳ª ½ÉÀå¹Úµ¿ÀÇ À̻󿡠ÀÇÇØ¼­ Á¤»óÀûÀΠ¼öÃàÀÌ ºÒ°¡´ÉÇÒ °æ¿ì¿¡ »ý±ä´Ù.
¿µ¹® pacemaker(of heart) ÇÑ±Û ½ÉÀå¹Úµ¿±â
¼³¸í   
  ½ÉÀåÀÇ Àü±âÀû ÀÚ±ØÀÌ º´ÀûÀΠ»óÅ·Π¹ß»ýÇÏÁö ¾Ê°Å³ª, È¤Àº ½É½Ç·Î Àß ÀüÇØÁöÁö ¾ÊÀ» ¶§ »ç¿ëÇÑ´Ù. ÀϽÃÀû ½ÉÀå¹Úµ¿±â¿Í ¿µ±¸Àû ½ÉÀå¹Úµ¿±â°¡ ÀÖÀ¸¸ç, °¢±â ¾²À̴ ¿ëµµ´Â º´¿¡ µû¶ó ´Ù¸£´Ù.
  
  ¿äÁò¿¡ ³ª¿À´Â ½ÉÀå ¹Úµ¿±â´Â °ÇÀüÁöÀÇ ¼ö¸íµµ ¹Ý¿µ±¸ÀûÀ̸ç, ¹Û¿¡¼­ Á¶Á¤ÇÒ ¼ö ÀÖ°í, ¿îµ¿À̳ª ½ºÆ®·¹½º »óȲ¿¡ ´ëÇÑ ½ÉÀåÀÇ ºü¸¥ ¿îµ¿¿¡µµ Àß ÀûÀÀÇÒ ¼ö ÀÖµµ·Ï ¸¸µé¾îÁ® ÀÖ´Ù.
¿µ¹® heart disease ÇÑ±Û ½ÉÀ庴
¼³¸í   
  ¼øÈ¯±â Áúȯ Áß ½ÉÀåÀÇ º´. ÀϹÝÀûÀ¸·Î ½ÉÀåÇ÷°üÀ̳ª ½ÉÀåÀÇ º´µµ Æ÷ÇԵȴÙ. º´ÅÍÀÇ ºÎÀ§¿¡ ÀÇÇÑ º´¸®ÇغÎÇÐÀû ºÐ·ù¿Í º´Àο¡ ÀÇÇÑ ºÐ·ù°¡ ÀÖ´Ù. ÀüÀڴ ¼ö ½Ê ³â ÀüºÎÅÍ ¾²¿©Á® ¿ÔÀ¸³ª ±Ù³â¿¡ ¿Í¼­ º»ÁúÀûÀΠ¿øÀοä¹ýÀÌ °¡´ÉÇϰԠµÈ ÀÌÈĴ ÈÄÀÚÀÇ ºÐ·ù°¡ ÀÇÀǰ¡ À־ ¸¹ÀÌ ¾²À̰ԠµÇ¾ú´Ù. º´ÅÍ ºÎÀ§·Î´Â ½É³»¸·(ÆÇ¸·)-½ÉÀå±Ù-½ÉÀ帷, ±× ¹ÛÀÇ °ÍÀ» µé ¼ö ÀÖÀ¸¸ç, °¢°¢ ½É³»¸·¿°-½ÉÀåÆÇ¸·Áõ-½É±Ù¿°-½É±Ù°æ»ö-½ÉÀ帷¿°-¼±Ãµ¼º ½ÉÀ庴(½ÉÀå±âÇü) µîÀÌÆ÷ÇԵȴÙ. º´Àκ°¿¡¼­´Â ½ÉÀå±âÇüÀ» ºñ·ÔÇÏ¿© ·ù¸¶Ä¡½º ½ÉÀ庴-¸Åµ¶¼º ½ÉÀ庴-°íÇ÷¾Ð¼º ½ÉÀ庴-½ÉÀ嵿¸Æ°æÈ­¼º ½ÉÀ庴-Æó¼º½ÉÀå-¼¼±Õ¼º ½É³»¸·¿°-½ÉÀå½Å°æÁõ µîÀ¸·Î ³ª´©¾îÁö¸ç, ºÎÁ¤¸ÆÀ̳ª ¹æ½ÇÂ÷´Ü µîÀÇ ÀÚ±ØÀüµµ°èÀÇ Àå¾Ö¿¡ ÀÇÇÑ °Íµµ Áõ¼¼ÀÇ Çϳª·Î º¼ ¼ö ÀÖ´Ù. ½ÉÀ庴Àº ÀÚ°¢ÀûÀ¸·Î´Â ¹«Áõ¼¼ÀΠ°Í¿¡¼­ºÎÅÍ ½ÉÀå±â´É»ó½Ç·Î È£Èí°ï¶õ±îÁö ÀÖ´Ù.
¿µ¹® septal defects of heart ÇÑ±Û ½ÉÀåÀÇ Áß°Ý °á¼Õ
¼³¸í   
  ¼±ÃµÀûÀ¸·Î ½ÉÀå ³»ÀÇ ½É¹æ»çÀÌÁß°Ý(interatrial septum)À̳ª ½É½Ç»çÀÌÁß°Ý(interventricular septum)ÀÌ °á¼ÕµÇ¾î Ç÷·ù°¡ Á¤»óÀûÀ¸·Î È帣Áö ¾Ê´Â °æ¿ì. Á¤»óÀûÀΠ°æ¿ì Ç÷·ù´Â Á¤¸Æ¿¡¼­ ¿ì½É¹æÀ¸·Î ¸ð¿© ¿ì½É½ÇÀ» °ÅÄ£µÚ Æó·Î °¡¼­ »ê¼Ò¸¦ °ø±Þ¹Þ°í ´Ù½Ã ¿Þ½É¹æ, ¿Þ½É½ÇÀ» Â÷·Ê·Î °ÅÃÄ ´ëµ¿¸ÆÀ¸·Î °£´Ù. ÇÏÁö¸¸, ÀÌ °æ¿ì´Â Ç÷·ù°¡ ¾Ð·ÂÀÌ ³ôÀº ¿Þ½É¹æÀ̳ª ¿Þ½É½Ç¿¡¼­ ¾Ð·ÂÀÌ ³·Àº ¿ì½É¹æÀ̳ª ¿ì½É½Ç·Î È帣°Ô µÈ´Ù. µû¶ó¼­ µ¿¸ÆÇǿ͠Á¤¸ÆÇǰ¡ ¼¯À̰ԠµÇ°í, È¯Àڴ ȣÈí°ï¶õ, ¼ºÀå¹ßÀ°Àå¾Ö, ½ÉÀâÀ½ µîÀÌ ³ªÅ¸³ª°í, ½ÉÇÑ °æ¿ì Ã»»öÁõÀ¸·Î ¹ßÀüÇϱ⵵ ÇÑ´Ù. Ä¡·á´Â ¼ö¼úÀûÀ¸·Î ÀÌ °á¼ÕºÎÀ§¸¦ ¸·¾Æ ÁÖ¾î¾ß ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • longitudinal study
    ÃßÀû¿¬±¸
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ¿¬±¸
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀÓ»óÀü½ÃÇè, ÀüÀӻ󿬱¸
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸
  • study
    1. ¿¬±¸, Á¶»ç 2. °Ë»ç, °Ë»ö
  • study design
    ¿¬±¸¼³°è
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ¿¬±¸
  • population study
    Àα¸Á¶»ç
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸, ¾Õ¹æÇ⿬±¸, Àü¸Á¿¬±¸
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸, ȸ°í¿¬±¸
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • single blinding study
    ´Ü¼ø¸Í°Ë¹ý
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • feasibility study
    °¡´É¼º¿¬±¸
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç
  • follow-up study
    ÃßÀûÁ¶»ç
  • infection control study
    °¨¿°°ü¸®Á¶»ç
  • intervening study
    °³ÀÔ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • microbiologic study
    ¹Ì»ý¹°Çа˻ç
  • migrant study
    ÀÌÁֹבּ¸
  • mixing study
    È¥ÇÕ°Ë»ç
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • nonconcurrent study
    ºñµ¿½ÃÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ½ÇÇè
  • population study
    Àα¸Á¶»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Fourth heart sound
    Á¦4½ÉÀ½(ãýëå)
  • Heart beat
    ½É¹Úµ¿(ãýÚÑÔÑ)
  • Heart block
    ½ÉÂ÷´Ü(ãýó´Ó¨)
  • Heart failure
    ½ÉºÎÀü(ãýÜôîï)
  • Heart murmur
    ½ÉÀâÀ½(ãýíÚëå)
  • Heart muscle
    ½É±Ù(ãýÐÉ)
  • Heart rate
    ½É¹Ú¼ö(ãýÚÑâ¦)
  • Heart sounds
    ½ÉÀ½(ãýëå)
  • Heart valves
    ½ÉÆÇ¸·(ãý÷ûد)
  • Heart-lung machines
    Àΰø½ÉÆó±â(ìÑÍïãýøËÐï)
  • Incomplete heart block
    ºÒ¿ÏÀü ½ÉÂ÷´Ü(ÝÕèÇîï ãýó´Ó¨)
  • acquired heart disease =AHD
    ÈÄõ¼º ½ÉÁúȯ(¡­ãýòðü´).
  • acute heart failure
    ±Þ¼º ½ÉºÎÀü(¡­ãýÝÕîï).
  • air in heart
    ½É±â(Áõ)(ãýѨñø).
  • aortic configuration = sabot heart
    ´ëµ¿¸Æ(ÆÇ¸·Áúȯ) Çü»ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇÐ<ÀÚ>°Ë»ç
  • nested case control study
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • retrospective study
    ÈÄÇâÀû¿¬±¸
  • single blind study
    ´ÜÀÏ<¼ø>¸Í°Ë¹ý.
  • time study
    ½Ã°£¿¬±¸(¡­æÚϼ).
  • tracer study
    ÃßÀûÀÚ¿¬±¸(õÚîæíºæÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬±¸(¡­æÚϼ).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heart catheterization
    ½ÉÀåÄ«Å×Å׸£¹ý
  • heart failure
    ½ÉºÎÀü
  • heart lung machine
    ½ÉÆó±â, Àΰø½ÉÆóÀåÄ¡±â
  • heart lung ratio
    ½ÉÆó°è¼ö
  • heart scan
    ½ÉÁÖ»ç
  • heart shadow
    ½ÉÀåÀ½¿µ
  • high output heart failure
    °í¹ÚÃ⼺½ÉºÎÀü
  • hypoplastic left heart syndrome
    Á½ɽÇÇü¼ººÎÀüÁõÈıº
  • ischemic heart disease
    ÇãÇ÷¼º ½ÉÁúȯ
  • restrictive heart disease
    ±¸¼Ó¼º½ÉÁúȯ
  • rheumatic heart disease
    ·ù¸¶Æ¼½º¼º½ÉÁúȯ
  • sabot heart
    ¸ñÈ­½É
  • unilocular heart
    Àϰ­½É
  • valvular heart disease
    ÆÇ¸·¼º½ÉÁúȯ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EF study Ejection-Fraction study
KAP study Knowledge, Attitude & Practice study
AASK African American Study of Kidney Diseases and Hypertension Pilot Study
NCS National Collaborative Study; neocarcinostatin; nerve conduction study; newborn calf serum; no conce...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
Study B study
Study I study
ACC-AHA American College of Cardiology - American Heart Association
AHA American Heart Association
AH Artificial heart
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • phase 1 study
    ÀÓ»ó Á¦1»ó ½ÃÇè
  • prospective study
    ÀüÇâÀû ¿¬±¸, ÃßÀû ¿¬±¸
  • psychophysical study
    Á¤½Å ½ÅüÇÐ ¿¬±¸
  • psychophysiological study
    Á¤½Å »ý¸®ÇÐÀû ¿¬±¸
  • radionuclei study
    ÇÙ ¹æ»ç¼± ÃÔ¿µ
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • secretory study
    ºÐºñ °Ë»ç
  • study cast
    ¿¬±¸¿ë ¸ðÇü, Áø´Ü ¸ðÇü
    µ¿ÀǾî=diagnostic cast.
  • video-urodynamic study
    ºñµð¿À ¿ä¿ªÇÐ °Ë»ç
  • acquired heart disease
    ÈÄõ¼º ½É Áúȯ
    »ýÈÄ¿¡ ¾ò¾îÁø ½ÉÀå Áúȯ.
  • acute heart failure
    ±Þ¼º ½ÉºÎÀü
    ±Þ¼º ¼øÈ¯ ºÎÀüÀÇ ÇϳªÀÌ°í ¿øÀÎÀÌ ½ÉÀå¿¡ ÀÖÀ» ¶§¸¦ ¸»ÇÑ´Ù. ±Þ¼º Á½ɺÎÀüÀº °íÇ÷¾Ð, ´ëµ¿¸ÆÆÇ ¹× ½Â¸ðÆÇ¸·Áõ, ½É±Ù¿°, Ư¹ß¼º ½É±ÙÁõ µî¿¡ À־ Á½ɽǿ¡ °©Àڱ⠻ý±ä ¼öÃà ºÎÀüÀ¸·Î ÀÎÇØ¼­ »ý±â´Â °ÍÀ̰í, Æó ¿ïÇ÷À» °¡Á®¿Í ¹ßÀÛ¼º È£Èí°ï¶õÀÌ »ý±ä´Ù. ±Þ¼º ¿ì½ÉºÎÀüÀº ±Þ¼º Æó»öÀü, ½É±Ù¿° µî¿¡ ÀÇÇØ ¿ì½ÉÀÇ ±Þ¼º ¼öÃà ºÎÀüÀÌ »ý°åÀ» ¶§¿¡ ÀÏÀ¸Å°°í ¿ì½ÉÀ¸·ÎÀÇ È¯·ù °¨¼Ò·Î ÀÎÇØ¼­ Ç÷¾ÐÀúÇÏ, ¼îÅ©°¡ »ý±ä´Ù. È£Èí°ï¶õ, ºóÈ£ÈíÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù.
  • American Heart Association
    ¹Ì±¹½ÉÀ庴ÇÐȸ, ¹Ì±¹½ÉÀåÇÐȸ
  • apex of heart
    ½ÉÀ峡, ½É÷ºÎ, ½É÷
  • artificial heart lung apparatus
    Àΰø ½ÉÆó
  • backward heart failure
    ÈÄÇ⠽ɺÎÀü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
study, crossover A type of clinical trial in which the study subjects receive each treatment in a random order. In this type of study, every patient serves as his or her own control.
(12 Dec 1998)
study, cross-sectional A study done at one time, not over the course of time. A cross-sectional study a disease such as aids might be designed to learn its prevalence and distribution within the population at one point in time. Also known as a synchronic study.
(12 Dec 1998)
study, diachronic See: Study, longitudinal.
(12 Dec 1998)
study, longitudinal A study done over the passage of time. For example, a longitudinal study of children with down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a diachronic study. The opposite of a cross-sectional (synchronic) study.
(12 Dec 1998)
study, preclinical A study to test a drug, procedure or medical treatment in animals. The aim is to collect data in support of safety. Preclinical studies are required before clinical trials can be started.
(12 Dec 1998)
study, synchronic See: Study, cross-sectional.
(12 Dec 1998)
synchronic study <epidemiology> A study in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with longitudinal studies which are followed over a period of time.
Synonym: horizontal study.
(18 Jul 2002)
diachronic study A study done over the course of time. For example, a longitudinal study of children with Down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a longitudinal study. The opposite of a synchronic (cross-sectional) study.
(12 Dec 1998)
double-blind study A study in which neither the experimenter nor any other assessor of the results, including patients, know which group is subject to which procedure, thus helping assure that the biases or expectations of either will not influence the results.
(05 Mar 2000)
epidemiologic study characteristics Types and formulations of studies used in epidemiological and clinical research.
(12 Dec 1998)
twin study A method of detecting genetic causes in human traits and genetic factors in behaviour using sets of twins.
(12 Dec 1998)
foetal doppler study <radiology> Non-stress test (NST), external monitoring for 20 minutes; poor specificity, greater than4 foetal heart accelerations (greater than15 bpm over baseline for 15 seconds) following foetal movement in foetus greater than34 weeks, no heart accelerations in immaturity, sleep, maternal sedation contraction stress test (CST), external monitoring after oxytocin or maternal breast stimulation, greater than 3 uterine contraction in 10 minutes; 50% specificity uterine and umbilical artery waveform, elevated systolic:diastolic ratio = increased vascular resistance foetal aortic flow volume, 185-246 ml/kg/min see also: biophysical profile, intrauterine growth retardation (IUGR)
(12 Dec 1998)
follow-up study Study in which persons exposed to risk or given a designated preventive or therapeutic regimen are observed over a period or at intervals to determine the outcome of the exposure or regimen.
(05 Mar 2000)
longitudinal study <epidemiology> A study taking place over time. If individuals are followed, this is a longitudinal cohort study. If individuals are not followed, but classes (usually age classes) are restudied, this is a longitudinal cross-sectional study.
The converse of a horizontal study.
(05 Dec 1998)
abnormal heart chamber dimensions <radiology> Left ventricular volume overload, left ventricular hypertrophy, right ventricular volume overload, right ventricular hypertrophy, fixed subvalvular aortic stenosis, hypoplastic left/right ventricle; common ventricle, congestive cardiomyopathy
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heart's-ease
    ¸¶À½ÀÇ Æò¿Â
  • heart-stricken
    ½½ÇÄ¿¡ Á¥¾î ¹ö¸°
  • heart-struck
    ½½ÇÄ¿¡ Á¥¾î ¹ö¸°
  • learn by heart
    ¾Ï±âÇÏ´Ù
  • lose heart
    ³«´ãÇÏ´Ù
  • take heart
    Èñ¸ÁÀ» °®´Ù
  • take to heart
    ÁøÁöÇÏ°Ô ¹Þ¾ÆµéÀÌ´Ù
  • Purple Heart
    ¸í¿¹ »óÀ̱âÀå;(ÇÏÆ®Çü)ÈïºÐÁ¦
  • bleeding heart
    ±Ý³¶È­
  • heart
    ½ÉÀå;°¡½¿(¼Ó);¸¶À½;¸¶À½¼Ó;º»½É;¾ÖÁ¤;¿ë±â;±â·Â;¿ø±â;Áß½É;Áß¾Ó;ÇÙ½É
  • heart attack
    =HEART FAILURE
  • heart cherry
    ¾ÞµÎÀÇ ÀÏÁ¾(½ÉÀå ¸ð¾çÀÇ)
  • heart disease
    ½ÉÀ庴
  • heart disease
    ½ÉÀ庴
  • heart failure
    ½ÉÀ帶ºñ;½ÉÀå¹ßÀÛ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á